1. Home
  2. FINV vs AVLN Comparison

FINV vs AVLN Comparison

Compare FINV & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinVolution Group

FINV

FinVolution Group

HOLD

Current Price

$3.37

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$38.23

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FINV
AVLN
Founded
2007
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2017
2026

Fundamental Metrics

Financial Performance
Metric
FINV
AVLN
Price
$3.37
$38.23
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.10
N/A
AVG Volume (30 Days)
1.1M
170.6K
Earning Date
05-19-2026
N/A
Dividend Yield
6.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.58
N/A
P/E Ratio
$3.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.22
$24.90
52 Week High
$8.05
$40.17

Technical Indicators

Market Signals
Indicator
FINV
AVLN
Relative Strength Index (RSI) 29.94 62.07
Support Level N/A $26.38
Resistance Level $5.17 $40.08
Average True Range (ATR) 0.22 1.98
MACD -0.08 -0.22
Stochastic Oscillator 12.72 72.20

Price Performance

Historical Comparison
FINV
AVLN

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: